Product Description
CPB526 is a 1+1 bivalent bispecific structured after Rilvegostomig but designed to simultaneously target mouse programmed cell death protein 1 (PD-1, CD279) and mouse T cell immunoreceptor with Ig and ITIM domains (TIGIT). This bispecific was designed to simultaneous block two key inhibitory checkpoints that suppress immune responses in the tumor microenvironment to overcome tumor-induced immune suppression. Blocking PD-1 prevents the delivery of inhibitory signals that otherwise drive T-cell exhaustion and tumor evasion and facilitates T-cell proliferation and cytokine production. Binding to TIGIT blocks interaction with ligands like CD155 (PVR) and CD112, preventing the transmission of inhibitory signals mediated by TIGITs ITIM/ITT-like domains.
* VAT and shipping costs not included. Errors and price changes excepted
